๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C

โœ Scribed by Mandana Khalili; Cheryl Denham; Robert Perrillo

Book ID
119388846
Publisher
Nature Publishing Group
Year
2000
Tongue
English
Weight
115 KB
Volume
95
Category
Article
ISSN
0002-9270

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Merimepodib, pegylated interferon, and r
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
โœ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 240 KB ๐Ÿ‘ 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a